182 related articles for article (PubMed ID: 37828026)
1. Oncogenic context shapes the fitness landscape of tumor suppression.
Blair LM; Juan JM; Sebastian L; Tran VB; Nie W; Wall GD; Gerceker M; Lai IK; Apilado EA; Grenot G; Amar D; Foggetti G; Do Carmo M; Ugur Z; Deng D; Chenchik A; Paz Zafra M; Dow LE; Politi K; MacQuitty JJ; Petrov DA; Winslow MM; Rosen MJ; Winters IP
Nat Commun; 2023 Oct; 14(1):6422. PubMed ID: 37828026
[TBL] [Abstract][Full Text] [Related]
2. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
[TBL] [Abstract][Full Text] [Related]
3. A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer.
Cai H; Chew SK; Li C; Tsai MK; Andrejka L; Murray CW; Hughes NW; Shuldiner EG; Ashkin EL; Tang R; Hung KL; Chen LC; Lee SYC; Yousefi M; Lin WY; Kunder CA; Cong L; McFarland CD; Petrov DA; Swanton C; Winslow MM
Cancer Discov; 2021 Jul; 11(7):1754-1773. PubMed ID: 33608386
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
5. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
[TBL] [Abstract][Full Text] [Related]
6. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M
Cancer Res; 2013 Nov; 73(21):6448-61. PubMed ID: 24019382
[TBL] [Abstract][Full Text] [Related]
7. TSPAN6 is a suppressor of Ras-driven cancer.
Humbert PO; Pryjda TZ; Pranjic B; Farrell A; Fujikura K; de Matos Simoes R; Karim R; Kozieradzki I; Cronin SJF; Neely GG; Meyer TF; Hagelkruys A; Richardson HE; Penninger JM
Oncogene; 2022 Apr; 41(14):2095-2105. PubMed ID: 35184157
[TBL] [Abstract][Full Text] [Related]
8. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.
Maeda Y; Tsuchiya T; Hao H; Tompkins DH; Xu Y; Mucenski ML; Du L; Keiser AR; Fukazawa T; Naomoto Y; Nagayasu T; Whitsett JA
J Clin Invest; 2012 Dec; 122(12):4388-400. PubMed ID: 23143308
[TBL] [Abstract][Full Text] [Related]
9. Mutation of the LXCXE binding cleft of pRb facilitates transformation by ras in vitro but does not promote tumorigenesis in vivo.
Talluri S; Francis SM; Dick FA
PLoS One; 2013; 8(8):e72236. PubMed ID: 23936539
[TBL] [Abstract][Full Text] [Related]
10. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.
Ambrogio C; Barbacid M; Santamaría D
Oncogene; 2017 Apr; 36(16):2309-2318. PubMed ID: 27775074
[TBL] [Abstract][Full Text] [Related]
11. Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis.
Best SA; Vandenberg CJ; Abad E; Whitehead L; Guiu L; Ding S; Brennan MS; Strasser A; Herold MJ; Sutherland KD; Janic A
Cell Death Dis; 2020 Oct; 11(10):877. PubMed ID: 33082333
[TBL] [Abstract][Full Text] [Related]
12. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
[TBL] [Abstract][Full Text] [Related]
14. Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells.
Kumazaki M; Shimomura I; Kiyono T; Ochiya T; Yamamoto Y
Biochem Biophys Res Commun; 2020 Apr; 525(2):483-490. PubMed ID: 32111352
[TBL] [Abstract][Full Text] [Related]
15. Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma.
Yousefi M; Andrejka L; Szamecz M; Winslow MM; Petrov DA; Boross G
Proc Natl Acad Sci U S A; 2023 Sep; 120(38):e2303224120. PubMed ID: 37695905
[TBL] [Abstract][Full Text] [Related]
16. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
Andreadi C; Cheung LK; Giblett S; Patel B; Jin H; Mercer K; Kamata T; Lee P; Williams A; McMahon M; Marais R; Pritchard C
Genes Dev; 2012 Sep; 26(17):1945-58. PubMed ID: 22892241
[TBL] [Abstract][Full Text] [Related]
17. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
[TBL] [Abstract][Full Text] [Related]
18. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
[No Abstract] [Full Text] [Related]
19. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
[TBL] [Abstract][Full Text] [Related]
20. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]